Pieris Pharmaceuticals Inc (OQ:PIRS)

Mar 27, 2024 08:00 am ET
Pieris Pharmaceuticals Announces Strategy to Maximize Partnered Milestone and Royalty Potential
BOSTON, MA / ACCESSWIRE / March 27, 2024 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) provided a corporate update today announcing a strategy to maximize its ability to capture the potential milestones from its 4-1BB bispecific Mabcalin® (antibody-Anticalin fusion) protein immuno-oncology assets partnered with Pfizer (formerly Seagen), Boston Pharmaceuticals, and Servier. After considering an extensive range of options, the Company's Board of Directors decided to implement this new strategy along with relevant cost-saving measures that are expe
Sep 27, 2023 09:31 am ET
Thinking about buying stock in Soleno Therapeutics, Lovesac, Pieris Pharmaceuticals, Lithium Americas, or Fisker?
NEW YORK, Sept. 27, 2023 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for SLNO, LOVE, PIRS, LAC, and FSR.
Aug 17, 2023 08:00 am ET
Pieris Pharmaceuticals Announces Milestone Achievement for Boston Pharmaceuticals' Initiation of Phase 1/2 Study of BOS-342, a 4-1BB/GPC3 Immuno-Oncology Bispecific
BOSTON, MA / ACCESSWIRE / August 17, 2023 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS), a clinical-stage biotechnology company focused on novel biotherapeutics through its proprietary Anticalin® technology platform for respiratory diseases and cancer, today announced that the Company has achieved an undisclosed milestone payment from Boston Pharmaceuticals. The milestone is based on dosing the first patient in a Boston Pharmaceutical-sponsored phase 1/2 study of BOS-342 (formerly PRS-342), a 4-1BB/GPC3 immuno-oncology antibody-Anticalin fusion
Jul 18, 2023 09:15 am ET
Pieris Pharmaceuticals Provides Strategic Update and Announces Restructuring
BOSTON, MA / ACCESSWIRE / July 18, 2023 / Pieris Pharmaceuticals, Inc. (Nasdaq:PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for respiratory diseases and cancer, today provided a strategic update following recent events that have impacted its inhaled respiratory franchise, including AstraZeneca's discontinuation of enrollment of the Phase 2a study for elarekibep. AstraZeneca has now informed the Company of its decision to terminate the parties' R&D collab
Jun 21, 2023 07:00 am ET
Pieris Pharmaceuticals Announces AstraZeneca Discontinuation of Phase 2a Trial of Elarekibep (PRS-060/AZD1402) Due to New Non-Clinical Safety Findings From 13-week Toxicology Study
BOSTON, MA / ACCESSWIRE / June 21, 2023 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for respiratory diseases and cancer indications, announced that partner AstraZeneca yesterday communicated to Pieris its decision to discontinue and cease dosing in the ongoing clinical studies of elarekibep, an inhaled IL-4 receptor alpha inhibitor under development for the treatment of asthma. This decision was based on lung findings
Jun 02, 2023 04:30 pm ET
Pieris Pharmaceuticals to Present at Jefferies 2023 Healthcare Conference
BOSTON, MA / ACCESSWIRE / June 2, 2023 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for respiratory and cancer diseases, today announced that Stephen Yoder, president and chief executive officer of Pieris, will participate in a fireside chat at the Jefferies Healthcare Conference on Friday, June 9, 2023 at 10:00 a.m. ET in New York City.
May 22, 2023 08:00 am ET
Pieris Pharmaceuticals Announces Presentation of Encouraging Preclinical Data for PRS-400 at ATS 2023 International Conference
BOSTON, MA / ACCESSWIRE / May 22, 2023 / Pieris Pharmaceuticals, Inc. (Nasdaq:PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for respiratory diseases, cancer, and other indications, announced the presentation of preclinical data from the Company's inhaled Jagged-1 targeting program, PRS-400, at the annual American Thoracic Society (ATS) International Conference being held in Washington, D.C. May 19-24, 2023. The poster presentation will
May 21, 2023 08:00 am ET
Pieris Pharmaceuticals Announces Presentation of Promising Preclinical Data for PRS-220 at ATS 2023 International Conference
BOSTON, MA / ACCESSWIRE / May 21, 2023 / Pieris Pharmaceuticals, Inc. (Nasdaq:PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for respiratory diseases, cancer, and other indications, announced the presentation of preclinical data from the Company's inhaled connective tissue growth factor (CTGF) antagonist program, PRS-220, for idiopathic pulmonary fibrosis (IPF) at the annual American Thoracic Society (ATS) International
May 10, 2023 07:00 am ET
Pieris Pharmaceuticals Reports First Quarter 2023 Financial Results and Business Updates
COMPANY TO HOST AN INVESTOR CONFERENCE CALL TODAY, WEDNESDAY, MAY 10, 2023, AT 8:00 AM EDT
May 04, 2023 08:00 am ET
Pieris Pharmaceuticals Announces Successful Completion of Safety Review for 10 mg Dose of Phase 2a Trial of Elarekibep (PRS-060/AZD1402)
BOSTON, MA / ACCESSWIRE / May 4, 2023 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for respiratory diseases, cancer, and other indications, today announced the successful safety review of the 10 mg dry powder dose safety cohort from the ongoing multi-center, placebo-controlled phase 2a study of dry powder inhaler-formulated elarekibep (PRS-060/AZD1402). The successful review of the 10 mg dose provides additional data su
May 02, 2023 04:30 pm ET
Pieris Pharmaceuticals to Host First Quarter 2023 Investor Call and Provide Corporate Update on May 10, 2023
BOSTON, MA / ACCESSWIRE / May 2, 2023 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for respiratory diseases, cancer and other indications, today announced that it will host its first quarter 2023 investor call on Wednesday, May 10, 2023, at 8:00 AM EDT to discuss financial results and provide a corporate update.
Apr 17, 2023 08:00 am ET
Pieris Pharmaceuticals Announces Presentation of Positive Clinical Data for Cinrebafusp Alpa (PRS-343) At 2023 AACR Annual Meeting
BOSTON, MA / ACCESSWIRE / April 17, 2023 / Pieris Pharmaceuticals, Inc. (Nasdaq:PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for respiratory diseases, cancer, and other indications, announced the presentation of cinrebafusp alfa (PRS-343) clinical results from the Company's study in 2L+ HER2-positive gastric cancer at the American Association for Cancer Research annual meeting being held in Orlando, Florida on April 14
Mar 29, 2023 07:00 am ET
Pieris Pharmaceuticals Reports Full-Year 2022 Financial Results and Business Updates
COMPANY TO HOST AN INVESTOR CONFERENCE CALL TODAY, WEDNESDAY, MARCH 29, 2023, AT 8:00 AM EDT
Mar 24, 2023 05:00 pm ET
Pieris Pharmaceuticals to Host Year End 2022 Investor Call and Provide Corporate Update on March 29, 2023
BOSTON, MA / ACCESSWIRE / March 24, 2023 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS),a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for respiratory diseases, cancer and other indications, today announced that it will host its year-end 2022 investor call on Wednesday, March 29, 2023 at 8:00 AM EDT to discuss financial results and provide a corporate update.
Jan 10, 2023 08:00 am ET
Pieris Pharmaceuticals Announces $5 Million Milestone from Seagen for Initiation of Phase 1 Trial of CD228 x 4-1BB Bispecific Molecule (Mabcalin SGN-BB228 (PRS-346)
BOSTON, MA / ACCESSWIRE / January 10, 2023 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for respiratory diseases, cancer, and other conditions, today announced that the Company has achieved a $5 million milestone from Seagen. The milestone is based on dosing the first patient in a Seagen-sponsored phase 1 study of SGN-BB228 (PRS-346), a novel bispecific antibody-Anticalin molecule (Mabcalin™
Nov 23, 2022 08:00 am ET
Pieris Pharmaceuticals To Present at Evercore ISI Healthconx Conference
BOSTON, MA / ACCESSWIRE / November 23, 2022 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for respiratory diseases, cancer and other indications, today announced that management is scheduled to present at the Evercore ISI HealthCONx Conference on Thursday, December 1, 2022 at 12:10 PM ET. A webcast of the company's presentation will be available at this link.
Nov 09, 2022 08:00 am ET
Pieris Pharmaceuticals to Present at Jefferies London Healthcare Conference
BOSTON, MA / ACCESSWIRE / November 9, 2022 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for respiratory diseases, cancer and other indications, today announced that management is scheduled to present at the Jefferies London Healthcare Conference on Tuesday, November 15, 2022 at 7:25 AM GMT. A webcast of the company's presentation will be available at this link.
Nov 02, 2022 07:00 am ET
Pieris Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Corporate Update
COMPANY TO HOST AN INVESTOR CONFERENCE CALL ON WEDNESDAY, NOVEMBER 2, 2022 AT 8:00 AM EDT
Nov 01, 2022 09:15 am ET
Pieris Pharmaceuticals Announces Dosing of First Subject in Phase 1 Trial of Inhaled CTGF Inhibitor PRS-220
BOSTON, MA / ACCESSWIRE / November 1, 2022 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for respiratory diseases, cancer, and other indications, today announced that the first subject has been dosed in the phase 1 study of PRS-220, an oral inhaled Anticalin protein targeting connective tissue growth factor (CTGF) for the treatment of idiopathic pulmonary fibrosis
Oct 26, 2022 08:00 am ET
Pieris Pharmaceuticals To Host Third Quarter 2022 Investor Call and Provide Corporate Update on November 2, 2022
BOSTON, MA / ACCESSWIRE / October 26, 2022 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for respiratory diseases, cancer and other indications, today announced that it will host a third quarter 2022 investor call on Wednesday, November 2, 2022 at 8:00 AM EDT to discuss financial results and provide a corporate update.
Sep 08, 2022 04:01 pm ET
Pieris Pharmaceuticals to Present at H.C. Wainwright 24th Annual Global Investment Conference
BOSTON, MA / ACCESSWIRE / September 8, 2022 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for respiratory diseases, cancer and other indications, today announced that management is scheduled to present at the H.C. Wainwright 24th Annual Global Investment Conference on Wednesday, September 14, 2022 at 12:30 PM EDT. A webcast of the company's presentation will
Aug 24, 2022 08:00 am ET
Pieris Pharmaceuticals Announces Presentation of Preclinical Data for Inhaled Jagged-1 Inhibitor PRS-400 at ERS
BOSTON, MA / ACCESSWIRE / August 24, 2022 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for respiratory diseases, cancer, and other indications, today announced the presentation of preclinical data for PRS-400, an inhaled Jagged-1 Anticalin protein the Company is developing for the treatment of muco-obstructive lung diseases, at the European Respiratory Society (E
Aug 04, 2022 07:00 am ET
Pieris Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Corporate Update
COMPANY TO HOST AN INVESTOR CONFERENCE CALL ON THURSDAY, AUGUST 4, 2022 AT 8:00 AM EDT
Jul 28, 2022 07:20 am ET
Pieris Pharmaceuticals to Host Second Quarter 2022 Investor Call and Provide Corporate Update on August 4, 2022
BOSTON, MA / ACCESSWIRE / July 28, 2022 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for respiratory diseases, cancer and other indications, today announced that it will host a second quarter 2022 investor call on Thursday, August 4, 2022 at 8:00 AM EDT to discuss financial results and provide a corporate update.
Jun 02, 2022 08:00 am ET
Pieris Pharmaceuticals To Present at Jefferies Healthcare Conference
BOSTON, MA / ACCESSWIRE / June 2, 2022 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for respiratory diseases, cancer and other indications, today announced that management is scheduled to present at the Jefferies Healthcare Conference on Wednesday, June 8, 2022 at 8:00 AM EDT. A webcast of the company's presentation will be available at this link.
May 18, 2022 08:00 am ET
Pieris Pharmaceuticals To Present at H.C. Wainwright Global Investment Conference
BOSTON, MA / ACCESSWIRE / May 18, 2022 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for respiratory diseases, cancer and other indications, today announced that management is scheduled to present at the H.C. Wainwright Global Investment Conference on Wednesday, May 25, 2022 at 9:30 AM EDT. A webcast of the company's presentation will be available at this link.
May 11, 2022 07:00 am ET
Pieris Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Corporate Update
Company To Host an Investor Conference Call On Wednesday, May 11, 2022 At 8:00 Am EDT
May 04, 2022 08:00 am ET
Pieris Pharmaceuticals To Host First Quarter 2022 Investor Call and Provide Corporate Update on May 11, 2022
BOSTON, MA / ACCESSWIRE / May 4, 2022 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for respiratory diseases, cancer and other indications, today announced that it will host a first quarter 2022 investor call on Wednesday, May 11, 2022 at 8:00 AM EDT to discuss financial results and provide a corporate update.
Mar 01, 2022 07:00 am ET
Pieris Pharmaceuticals Reports Full-Year 2021 Financial Results and Provides Corporate Update
COMPANY TO HOST AN INVESTOR CONFERENCE CALL ON TUESDAY, MARCH 1, 2022 AT 8:00 AM EST
Feb 23, 2022 08:00 am ET
Pieris Pharmaceuticals To Host Full-Year 2021 Investor Call and Provide Corporate Update on March 1, 2022
BOSTON, MA / ACCESSWIRE / February 23, 2022 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for respiratory diseases, cancer and other indications, today announced that it will host a full-year 2021 investor call on Tuesday, March 1, 2022 at 8:00 AM EST to discuss financial results and provide a corporate update.
Jan 28, 2022 08:00 am ET
HTG Appoints Biopharmaceutical Industry Veteran Christopher Kiritsy to its Board of Directors
HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) (HTG), a life science company advancing precision medicine through its innovative transcriptome-wide profiling technology, announced it has appointed biopharmaceutical industry veteran Christopher...
Jan 14, 2022 08:00 am ET
Pieris Pharmaceuticals Announces Dosing of First Patient in Phase 2 Gastric Cancer Trial of 4–1BB/HER2 Bispecific Cinrebafusp Alfa
BOSTON, MA / ACCESSWIRE / January 14, 2022 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for respiratory diseases, cancer, and other indications, today announced that the first patient has been dosed in the phase 2 study of cinrebafusp alfa (PRS-343), a 4-1BB/HER2 Anticalin-based bispecific for the treatment of HER2-expressing gastric cancer. The two-arm, multicenter, open-label phase 2
Jan 03, 2022 07:00 am ET
Pieris Pharmaceuticals Announces Successful Completion of Safety Milestone and Initiation of Efficacy Portion of Phase 2a Trial of PRS-060/AZD1402
BOSTON, MA / ACCESSWIRE / January 3, 2022 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for respiratory diseases, cancer, and other indications, today announced the successful completion of the sponsor safety review of part 1a of the multi-center, placebo-controlled phase 2a study of dry powder inhaler-formulated PRS-060/AZD1402. PRS-060/AZD1402 is an IL-4 receptor alpha inhibitor under developmen
Nov 11, 2021 08:05 am ET
Pieris Pharmaceuticals To Participate In Upcoming Investor Conferences
BOSTON, MA / ACCESSWIRE / November 11, 2021 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for respiratory diseases, cancer, and other indications, today announced that members of the management team will participate in the following upcoming investor conferences:
Nov 08, 2021 08:00 am ET
Pieris Pharmaceuticals and Servier Announce Dosing of First Patient in Phase 1/2 Trial of 4-1BB/PD-L1 Bispecific PRS-344/S095012
BOSTON, MA and PARIS, FRANCE / ACCESSWIRE / November 8, 2021 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for respiratory diseases, cancer, and other indications, and Servier, a global pharmaceutical group, today announced that the first patient has been dosed in the phase 1/2 study of PRS-344/S095012, a next generation 4-1BB/PD-L1 Anticalin-based bispecific for the treatment of solid tumors, triggering a
Nov 02, 2021 07:00 am ET
Pieris Pharmaceuticals Reports Third Quarter 2021 Financial Results and Provides Corporate Update
Company To Host an Investor Conference Call on Tuesday, November 2, 2021 at 8:00 AM EDT
Oct 26, 2021 08:00 am ET
Pieris Pharmaceuticals To Host Third Quarter 2021 Investor Call and Provide Corporate Update on November 2, 2021
BOSTON, MA / ACCESSWIRE / October 26, 2021 / Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for respiratory diseases, cancer and other indications, today announced that it will host a third quarter 2021 investor call on Tuesday, November 2, 2021 at 8:00 AM EDT to discuss financial results and provide a corporate update.
Oct 06, 2021 08:00 am ET
Pieris Pharmaceuticals Announces Appointments of Chief Financial Officer and Chief Business Officer
BOSTON, MA / ACCESSWIRE / October 6, 2021 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for respiratory diseases, cancer, and other indications, today announced the promotions of Thomas Bures to Chief Financial Officer and Ahmed Mousa to Chief Business Officer.
Sep 09, 2021 08:00 am ET
Pieris Pharmaceuticals to Participate in Upcoming Investor Conferences
BOSTON, MA / ACCESSWIRE / September 9, 2021 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for respiratory diseases, cancer, and other indications, today announced that members of the management team will participate in the following upcoming investor conferences:
Aug 24, 2021 09:00 am ET
Pieris Pharmaceuticals Announces PRS-220 Presentation at ERS Highlighting Preclinical Data for CTGF Inhibitor
BOSTON, MA / ACCESSWIRE / August 24, 2021 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for respiratory diseases, cancer, and other indications, announced today the presentation of preclinical data for PRS-220, a connective tissue growth factor (CTGF) inhibitor the Company is developing for the treatment of idiopathic pulmonary fibrosis (IPF) via oral inhaled administration, at th
Aug 04, 2021 07:00 am ET
Pieris Pharmaceuticals Reports Second Quarter 2021 Financial Results and Provides Corporate Update
COMPANY TO HOST AN INVESTOR CONFERENCE CALL ON WEDNESDAY, AUGUST 4, 2021 AT 8:00 AM EDT
Aug 03, 2021 08:00 am ET
Pieris Pharmaceuticals Strengthens Executive R&D Leadership Team
BOSTON, MA / ACCESSWIRE / August 3, 2021 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for respiratory diseases, cancer, and other indications, today announced the appointment of Tim Demuth, M.D., Ph.D. as SVP and Chief Medical Officer. Dr. Demuth will oversee all clinical, medical, safety, and regulatory aspects at the Company. Pieris additionally announced the p
Jul 28, 2021 08:00 am ET
Pieris Pharmaceuticals to Host Second Quarter 2021 Investor Call and Provide Corporate Update on August 4, 2021
BOSTON, MA / ACCESSWIRE / July 28, 2021 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for respiratory diseases, cancer and other indications, today announced that it will host a second quarter 2021 investor call on Wednesday, August 4, 2021 at 8:00 AM EDT to discuss financial results and provide a corporate update.
Jun 25, 2021 08:30 am ET
Thinking about buying stock in Pieris Pharmaceuticals, Paysafe, Tonix Pharmaceuticals, FibroGen, or Arbutus Biopharma?
NEW YORK, June 25, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for PIRS, PSFE, TNXP, FGEN, and ABUS.
Jun 25, 2021 07:00 am ET
Pieris Pharmaceuticals Announces Inhaled CTGF Inhibitor PRS-220 for Idiopathic Pulmonary Fibrosis and 17 Million Dollar Grant From Bavarian Government To Accelerate Program Development for Post-COVID-
BOSTON, MA / ACCESSWIRE / June 25, 2021 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for respiratory diseases, cancer, and other indications, today announced the development of PRS-220, an oral inhaled Anticalin protein targeting connective tissue growth factor (CTGF), also known as CCN2, for the treatment of idiopathic pulmonary fibrosis (IPF). The Company also announced it has been selected to receive
Jun 24, 2021 09:31 am ET
Thinking about buying stock in DHI Group, Pieris Pharmaceuticals, Clover Health, Workhorse Group, or Vaxart?
NEW YORK, June 24, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for DHX, PIRS, CLOV, WKHS, and VXRT.
Jun 24, 2021 08:00 am ET
Pieris Pharmaceuticals Receives Orphan Drug Designation for Cinrebafusp Alfa for the Treatment of Gastric Cancer
BOSTON, MA / ACCESSWIRE / June 24, 2021 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for respiratory diseases, cancer, and other indications, today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to cinrebafusp alfa (PRS-343), a 4-1BB/HER2 bispecific, for the treatment of HER2-high and HER2-low expressing gastric cancers.
Jun 17, 2021 10:50 am ET
Thinking about buying stock in Pieris Pharmaceuticals, Midatech Pharma, ContextLogic, Barrick Gold, or Lordstown Motors?
NEW YORK, June 17, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for PIRS, MTP, WISH, GOLD, and RIDE.
May 25, 2021 08:00 am ET
Pieris Pharmaceuticals Announces Respiratory and Ophthalmology Collaboration with Genentech
BOSTON, MA / ACCESSWIRE / May 25, 2021 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for respiratory diseases, cancer, and other indications, today announced it has entered into a multi-program research collaboration and license agreement with Genentech, a member of the Roche Group, to discover, develop and commercialize locally delivered respiratory and ophthalmology therapies that leverage Pieris' proprietary Anticalin
May 20, 2021 08:00 am ET
Pieris Pharmaceuticals to Present at the Jefferies 2021 Virtual Healthcare Conference
BOSTON, MA / ACCESSWIRE / May 20, 2021 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for respiratory diseases, cancer, and other indications, announced today that management is scheduled to participate in a fireside chat at the Jefferies 2021 Virtual Healthcare Conference on Friday, June 4, 2021 at 1:00 PM EDT. A webcast of the company's presentation will be available at this link.
May 17, 2021 07:00 am ET
Pieris Pharmaceuticals Reports First Quarter 2021 Financial Results and Provides Corporate Update
COMPANY TO HOST AN INVESTOR CONFERENCE CALL ON MONDAY, MAY 17, 2021 AT 8:00 AM EDT
May 10, 2021 08:00 am ET
Pieris Pharmaceuticals to Host First Quarter 2021 Investor Call and Provide Corporate Update on May 17, 2021
BOSTON, MA / ACCESSWIRE / May 10, 2021 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for respiratory diseases, cancer and other indications, today announced that it will host a first quarter 2021 investor call on Monday, May 17, 2021 at 8:00 AM EDT to discuss financial results and provide a corporate update.
Apr 26, 2021 08:00 am ET
Pieris Pharmaceuticals and Boston Pharmaceuticals Enter into an Exclusive Worldwide Product License for PRS-342, a 4-1BB/GPC3 Immuno-Oncology Bispecific
BOSTON and CAMBRIDGE, MA / ACCESSWIRE / April 26, 2021 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) and Boston Pharmaceuticals today announced that the companies have entered into an exclusive product license agreement to develop PRS-342, a 4-1BB/GPC3 preclinical immuno-oncology Anticalin®-antibody bispecific fusion protein. Under the terms of the agreement, Boston Pharmaceuticals has exclusively licensed worldwide rights to PRS-342. Pieris will receive an upfront payment of $10 million and is further entitled to receive up to approxima
Apr 10, 2021 02:15 pm ET
Pieris Pharmaceuticals Presents Updated Phase 1 Monotherapy Data for 4-1BB/HER2 Bispecific Cinrebafusp Alfa and Preclinical Data for 4-1BB/PD-L1 Bispecific PRS-344/S095012 at 2021 AACR Annual Meeting
BOSTON, MA / ACCESSWIRE / April 10, 2021 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for respiratory diseases, cancer, and other indications, today presented a clinical data update from the phase 1 monotherapy study of cinrebafusp alfa (PRS-343), a 4-1BB/HER2 bispecific for the treatment of HER2-expressing solid tumors, in an oral presentation at the American Association for Cancer Research (AACR) Virtual Congress 2021. The Company also presented pr
Mar 30, 2021 07:00 am ET
Pieris Pharmaceuticals Reports Full-Year 2020 Financial Results and Provides Corporate Update
Company To Host an Investor Conference Call on Tuesday, March 30, 2021 at 8:00 AM EDT
Mar 25, 2021 08:00 am ET
Pieris Announces Amendment of Existing Immuno-oncology Multi-target Collaboration with Seagen, a Clinical Trial and Supply Agreement to Evaluate Cinrebafusp Alfa (PRS-343) in Combination with TUKYSA(R
BOSTON, MA / ACCESSWIRE / March 25, 2021 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for respiratory diseases, cancer, and other indications, today announced that Seagen has made a strategic equity investment in Pieris as part of an ongoing collaboration between the companies. In addition, the companies have entered into a clinical trial collaboration agreement to evaluate the safety and efficacy of c
Mar 23, 2021 08:00 am ET
Pieris Pharmaceuticals to Host Full-Year 2020 Investor Call and Provide Corporate Update on March 30, 2021
BOSTON, MA / ACCESSWIRE / March 23, 2021 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for respiratory diseases, cancer and other indications, today announced that it will host a full-year 2020 investor call on Tuesday, March 30, 2021 at 8:00 AM EDT to discuss financial results and provide a corporate update.
Feb 23, 2021 08:00 am ET
Pieris Pharmaceuticals to Participate in the Cowen 41st Annual Health Care Conference
BOSTON, MA / ACCESSWIRE / February 23, 2021 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for respiratory diseases, cancer, and other indications, today announced that Stephen S. Yoder, President and Chief Executive Officer of Pieris, is scheduled to participate in a GI Oncology and Pancreatic Cancer panel discussion at the Cowen 41st Annual Healthcare Conference on Tuesday, March 2, 2021 at 9:50 AM EST.
Feb 16, 2021 07:31 am ET
Thinking about buying stock in G1 Therapeutics, Strongbridge Biopharma, Soligenix, Pieris Pharmaceuticals, or Diffusion Pharmaceuticals?
NEW YORK, Feb. 16, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for GTHX, SBBP, SNGX, PIRS, and DFFN.
Jan 19, 2021 08:00 am ET
FDA Lifts Partial Clinical Hold on PRS-343 Phase 1 Studies
BOSTON, MA / ACCESSWIRE / January 19, 2021 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for respiratory diseases, cancer, and other indications, today announced that the U.S. Food and Drug Administration (FDA) has lifted the previously announced partial clinical hold on the phase 1 studies of PRS-343. As previously guided, the Company intends to move into a proof-of-concept study of PRS-343 in gastroesophageal c
Nov 10, 2020 08:00 am ET
Pieris Pharmaceuticals to Participate in Upcoming Investor Conferences
BOSTON, MA / ACCESSWIRE / November 10, 2020 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for respiratory diseases, cancer, and other indications, today announced that members of the management team will participate in the following upcoming investor conferences:
Nov 04, 2020 07:00 am ET
Pieris Pharmaceuticals Reports Third Quarter 2020 Financial Results and Provides Corporate Update
COMPANY TO HOST AN INVESTOR CONFERENCE CALL ON WEDNESDAY, NOVEMBER 4, 2020 AT 8:00 AM EST
Oct 28, 2020 08:00 am ET
Pieris Pharmaceuticals to Host Third Quarter 2020 Investor Call and Corporate Update on November 4, 2020
BOSTON, MA / ACCESSWIRE / October 28, 2020 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for respiratory diseases, cancer and other indications, today announced that it will host a third quarter 2020 investor call on Wednesday, November 4, 2020 at 8:00 AM EST to discuss financial results and provide a corporate update.
Sep 20, 2020 11:00 am ET
Pieris Pharmaceuticals Presents Updated Data from Phase 1 Monotherapy and Atezolizumab Combination Studies of 4-1BB/HER2 Bispecific PRS-343 at the European Society for Medical Oncology (ESMO) Virtual
BOSTON, MA / ACCESSWIRE / September 20, 2020 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for respiratory diseases, cancer, and other indications, today presented a clinical data update from the phase 1 monotherapy and atezolizumab combination studies of PRS-343, a 4-1BB/HER2 bispecific for the treatment of HER2-positive solid tumors, in an oral presentation at the European Society for Medical Oncology (ESMO) Virtual Congress 2020. PRS-343 continues
Sep 03, 2020 04:30 pm ET
Pieris Pharmaceuticals to Participate in Upcoming Investor Conferences
BOSTON, MA / ACCESSWIRE / September 3, 2020 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for respiratory diseases, cancer, and other indications, today announced that members of the management team will participate in the following upcoming investor conferences and will provide a corporate update:
Aug 10, 2020 07:00 am ET
Pieris Pharmaceuticals Reports Second Quarter 2020 Financial Results and Provides Corporate Update
Company to Host an Investor Conference Call on Monday, August 10, 2020 at 8:00 AM EDT
Aug 10, 2020 06:30 am ET
Pieris and Lilly Enter Into a Clinical Trial Collaboration to Evaluate Combination of PRS-343 With Ramucirumab and Paclitaxel in Gastric Cancer
BOSTON, MA / ACCESSWIRE / August 10, 2020 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for respiratory diseases, cancer, and other indications, today announced that it has entered into a clinical trial collaboration and supply agreement with Eli Lilly and Company to evaluate the safety and efficacy of combining Pieris' PRS-343, a 4-1BB/HER2 bispecific for HER2-positive tumors, with Lilly's ramucir
Aug 03, 2020 08:00 am ET
Pieris Pharmaceuticals to Host Second Quarter 2020 Investor Call and Corporate Update on August 10, 2020
BOSTON, MA / ACCESSWIRE / August 3, 2020 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for respiratory diseases, cancer and other indications, today announced that it will host a second quarter 2020 investor call on Monday, August 10, 2020 at 8:00 AM EDT to discuss financial results and provide a corporate update.
Jul 23, 2020 08:00 am ET
Pieris Pharmaceuticals Announces Oral Presentation of Phase 1 Data for 4-1BB/HER2 Bispecific PRS-343 at European Society for Medical Oncology (ESMO) Virtual Congress 2020
BOSTON, MA / ACCESSWIRE / July 23, 2020 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for respiratory diseases, cancer, and other indications, today announced that the Company will present phase 1 dose-escalation monotherapy and combination with atezolizumab data for PRS-343, a 4-1BB/HER2 bispecific for the treatment of HER2-positive solid tumors, in an oral presentation session at the European Society for Medical Oncology (ESMO)
Jul 21, 2020 07:27 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Pieris Pharmaceuticals, Inc. - PIRS
NEW YORK, July 21, 2020 /CNW/ -- Pomerantz LLP is investigating claims on behalf of investors Pieris Pharmaceuticals, Inc. ("Pieris" or the "Company") (NASDAQ: PIRS).   Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 7980.
Jul 21, 2020 07:27 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Pieris Pharmaceuticals, Inc. - PIRS
NEW YORK, July 21, 2020 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors Pieris Pharmaceuticals, Inc. ("Pieris" or the "Company") (NASDAQ: PIRS).   Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 7980.
Jul 20, 2020 04:05 pm ET
Pieris Pharmaceuticals Announces Partial Clinical Hold On PRS-343
BOSTON, MA / ACCESSWIRE / July 20, 2020 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for respiratory diseases, cancer, and other indications, today announced that its phase 1 studies of PRS-343 have been placed on partial clinical hold by the U.S. Food and Drug Administration (FDA) while Pieris conducts an additional in-use and compatibility study requested by the Agency. Currently-enrolled patients may continue
Jun 08, 2020 04:30 pm ET
Pieris Pharmaceuticals Announces Virtual 2020 Annual Meeting of Stockholders
BOSTON, MA / ACCESSWIRE / June 8, 2020 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for respiratory, cancer, and other diseases, announced today that due to the public health impact of the COVID-19 pandemic and to support the health and well-being of its stockholders, the 2020 Annual Meeting, scheduled for June 23, 2020 at 8:00 am Eastern Time, will be held in a virtual format only. An in-person meeting will not be held this year.
May 28, 2020 08:00 am ET
Pieris Pharmaceuticals to Present at the Jefferies 2020 Virtual Healthcare Conference
BOSTON, MA / ACCESSWIRE / May 28, 2020 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for respiratory diseases, cancer, and other indications, announced today that management will present at the Jefferies 2020 Virtual Healthcare Conference on Thursday, June 4, 2020 at 3:30 PM EDT. A webcast of the company's presentation will be available at this link.
May 11, 2020 07:00 am ET
Pieris Pharmaceuticals Reports First Quarter 2020 Financial Results and Provides Corporate Update
Company to Host an Investor Conference Call on Monday, May 11, 2020 at 8:00 Am Edt
May 04, 2020 08:00 am ET
Pieris Pharmaceuticals to Host First Quarter 2020 Investor Call and Corporate Update on May 11, 2020
BOSTON, MA / ACCESSWIRE / May 4, 2020 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for respiratory diseases, cancer and other indications, today announced that it will host a first quarter 2020 investor call on Monday, May 11, 2020 at 8:00 AM EDT to discuss financial results and provide a corporate update.
Mar 24, 2020 04:00 pm ET
Solebury Trout Announces Virtual Conference Series with Presentations from Life Science Companies
NEW YORK, NY / ACCESSWIRE / March 24, 2020 / Solebury Trout, a boutique investor relations and corporate communications firm, announced today that it will be hosting a Virtual Conference Series on March 26, March 31, and April 2, 2020, featuring leading companies from the life sciences industry. At the event, management teams will present a business overview and highlights using an online, digital meeting format.
Mar 23, 2020 04:30 pm ET
Pieris Pharmaceuticals Provides Update on Servier Collaboration
BOSTON, MA / ACCESSWIRE / March 23, 2020 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for respiratory, cancer, and other diseases, today announced an update on its strategic immuno-oncology collaboration with Servier, originally established in 2017. After conducting an extensive portfolio review, Servier has decided to focus on continued and accelerated development of the two most advanced programs, includ
Mar 12, 2020 07:00 am ET
Pieris Pharmaceuticals Reports Full-Year 2019 Financial Results And Provides Corporate Update
COMPANY TO HOST AN INVESTOR CONFERENCE CALL ON THURSDAY, MARCH 12, 2020 AT 8:00 AM EDT
Mar 05, 2020 08:00 am ET
Pieris Pharmaceuticals to Host Full-Year 2019 Investor Call and Corporate Update on March 12, 2020
BOSTON, MA / ACCESSWIRE / March 5, 2020 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for respiratory diseases, cancer and other indications, today announced that it will host a full-year 2019 investor call on Thursday, March 12, 2020 at 8:00 AM EDT to discuss financial results and provide a corporate update.
Feb 25, 2020 08:00 am ET
Pieris Pharmaceuticals to Participate in Upcoming Scientific and Investor Conferences
BOSTON, MA / ACCESSWIRE / February 25, 2020 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for respiratory diseases, cancer, and other indications, today announced that members of the management team will participate in the following upcoming scientific and investor conferences:
Nov 15, 2019 08:00 am ET
Pieris Pharmaceuticals Announces Asthma-focused Translational Research Collaboration with the University of Pittsburgh
BOSTON, MA / ACCESSWIRE / November 15, 2019 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for respiratory diseases, cancer, and other indications, today announced a research collaboration between the Company and the labs of University of Pittsburgh Professors Sally Wenzel, MD, and Anuradha Ray, PhD, focused on comprehensive immune phenotyping of severe asthmatic patients. Key objectives of the multi-year collaboratio
Nov 14, 2019 08:00 am ET
Pieris Pharmaceuticals to Participate in Upcoming Investor Conferences
BOSTON, MA / ACCESSWIRE / November 14, 2019 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for respiratory diseases, cancer, and other indications, today announced that members of the management team will participate in the following upcoming investor conferences:
Nov 11, 2019 07:00 am ET
Pieris Pharmaceuticals Reports Third Quarter 2019 Financial Results and Provides Corporate Update
Company to Host an Investor Conference Call On Monday, November 11, 2019 At 8:00 AM EST
Nov 09, 2019 12:00 pm ET
Pieris Pharmaceuticals Presents Data Demonstrating Monotherapy Clinical Benefit with 4-1BB/HER2 Bispecific PRS-343 in Phase 1 Escalation Study at the Society for Immunotherapy of Cancer (SITC) 2019 An
BOSTON, MA / ACCESSWIRE / November 9, 2019 / Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for respiratory diseases, cancer, and other indications, today announced the presentation of data from the phase 1 dose-escalation monotherapy study of PRS-343, a 4-1BB/HER2 bispecific for the treatment of HER2-positive solid tumors, in a late-breaking oral presentation at the Society for Immunotherapy of Cancer (SITC) Annual Meeting. PRS-343 demonstrated single-
Nov 07, 2019 08:00 am ET
Pieris Pharmaceuticals to Host R&D Event
BOSTON, MA / ACCESSWIRE / November 7, 2019 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for respiratory diseases, cancer and other indications, today announced that the Company will host an R&D event in New York on Tuesday, November 19, 2019 from 12:00 - 3:30 PM EST.
Nov 05, 2019 08:00 am ET
Pieris Pharmaceuticals to Present Phase 1 Data for 4-1BB/HER2 Bispecific PRS-343 at the Society for Immunotherapy of Cancer (SITC) Annual Meeting
BOSTON, MA / ACCESSWIRE / November 5, 2019 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for respiratory diseases, cancer and other indications, today announced that the Company will present phase 1 dose-escalation monotherapy data for PRS-343, a 4-1BB/HER2 bispecific for the treatment of HER2-positive solid tumors, in a late-breaking oral presentation session at the Society for Immunotherapy of Cancer (SITC) Annual Meeting in National Harb
Nov 04, 2019 08:00 am ET
Pieris Pharmaceuticals Announces $32 Million Private Placement and Potential Funding Mechanism for PRS-060 Co-development Opt-in
BOSTON, MA / ACCESSWIRE / November 4, 2019 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for respiratory diseases, cancer and other indications, today announced that it has entered into a securities purchase agreement with existing and new institutional investors to raise $32 million.
Nov 04, 2019 07:00 am ET
Pieris Pharmaceuticals to Host Third Quarter 2019 Investor Call and Corporate Update on November 11, 2019
BOSTON, MA / ACCESSWIRE / November 4, 2019 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for respiratory diseases, cancer and other indications, today announced that it will host a third quarter 2019 investor call on Monday, November 11, 2019 at 8:00 AM EST to discuss financial results and provide a corporate update.
Sep 26, 2019 09:35 am ET
Pieris Pharmaceuticals and AstraZeneca Present Multiple Ascending Dose Phase 1b Data for Inhaled IL4-Rα Antagonist AZD1402/PRS-060 at the 2019 European Respiratory Society International Congress
BOSTON, MA / ACCESSWIRE / September 26, 2019 / Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for respiratory diseases, cancer and other indications, today announced the presentation on October 1, 2019, of interim data from its placebo-controlled multiple ascending dose phase 1b study for AZD1402/PRS-060, an inhaled IL4-Rα antagonist being developed in collaboration with AstraZeneca intended for the treatment of ast
Sep 03, 2019 07:30 am ET
Pieris Pharmaceuticals Announces Changes to Senior Management Team
BOSTON, MA / ACCESSWIRE / September 3, 2019 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for respiratory diseases, cancer and other indications, today announced the appointment of Hitto Kaufmann, Ph.D. as Senior Vice President and Chief Scientific Officer and the departure of Allan Reine, M.D., Senior Vice President and Chief Financial Officer.
Aug 29, 2019 08:00 am ET
Aug 01, 2019 06:55 am ET
Pieris Pharmaceuticals Appoints Dr. Maya Said to its Board of Directors
BOSTON, MA / ACCESSWIRE / August 1, 2019 / Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for respiratory diseases, cancer and other indications, today announced that Maya R. Said, Sc.D., has joined the Company’s Board of Directors.
Jul 25, 2019 08:00 am ET
Pieris Pharmaceuticals To Host Second Quarter 2019 Investor Call And Corporate Update On August 1, 2019
BOSTON, MA / ACCESSWIRE / July 25, 2019 / Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for respiratory diseases, cancer and other indications, today announced that it will host a second quarter 2019 investor call on Thursday, August 1, 2019 at 8:00 AM (EDT) to provide a corporate update.
May 30, 2019 08:00 am ET
Pieris Pharmaceuticals to Present at the Jefferies 2019 Healthcare Conference
BOSTON, MA / ACCESSWIRE / May 30, 2019 / Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for respiratory, cancer and other diseases, announced today that Stephen Yoder, President and Chief Executive Officer of Pieris Pharmaceuticals, Inc., will present at the Jefferies 2019 Healthcare Conference in New York, New York on Thursday, June 6, 2019 at 3:30 PM (EDT). A webcast of the company's presentation will be available at this
May 22, 2019 02:30 pm ET
Pieris Pharmaceuticals and AstraZeneca Present Single- Ascending Dose Phase 1a Data for Inhaled IL-4Rα Antagonist AZD1402/PRS-060 at the American Thoracic Society (ATS) 2019 International Conference
BOSTON, MA / ACCESSWIRE / May 22, 2019 / Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for respiratory diseases, cancer and other indications, today announced the presentation of placebo-controlled single ascending dose Phase 1a data for AZD1402/PRS-060, an inhaled IL-4Rα antagonist being developed in collaboration with AstraZeneca intended for the treatment of asthma, at the American Thoracic Society (ATS) 2019 International Conference.
May 14, 2019 08:00 am ET
Pieris Pharmaceuticals to Present at the 2019 RBC Capital Markets Global Healthcare Conference
BOSTON, MA / ACCESSWIRE / May 14, 2019 / Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for respiratory, cancer and other diseases, announced today that Allan Reine, Senior Vice President and Chief Financial Officer of Pieris Pharmaceuticals, Inc. will present at the 2019 RBC Capital Markets Global Healthcare Conference in New York, New York on Tuesday, May 21, 2019 at 11:30 AM (EDT). A webcast of the company's presentation will be available at t
May 10, 2019 07:00 am ET
Pieris Pharmaceuticals Reports First Quarter 2019 Financial Results and Provides Corporate Update
Company To Host An Investor Conference Call On Friday, May 10, 2019 At 8:00 AM EDT
May 03, 2019 08:00 am ET
Pieris Pharmaceuticals to Host First Quarter 2019 Investor Call and Corporate Update on May 10, 2019
BOSTON, MA / ACCESSWIRE / May 3, 2019 / Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for respiratory diseases, cancer and other indications, today announced that it will host a first quarter 2019 investor call on Friday, May 10, 2019 at 8:00 AM (EDT) to discuss financial results and provide a corporate update.
Apr 10, 2019 07:40 am ET
New Research Coverage Highlights Fortive, Pieris Pharmaceuticals, CEVA, ManTech International, Cerus, and NN — Consolidated Revenues, Company Growth, and Expectations for 2019
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Fortive Corporation (NYSE:FTV), Pieris Pharmaceuticals, Inc....
Apr 03, 2019 08:50 am ET
Pieris Pharmaceuticals to Present at the 2019 H.C. Wainwright Global Life Sciences Conference
BOSTON, MA / ACCESSWIRE / April 3, 2019 / Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for respiratory, cancer and other diseases, announced today that Allan Reine, Senior Vice President and Chief Financial Officer of Pieris Pharmaceuticals, Inc. will present at the 2019 H.C. Wainwright Global Life Sciences Conference in London, U.K. on Monday, April 8, 2019 at 1:30 PM (GMT). A webcast of the company's presentation will be available at thi
Apr 02, 2019 08:00 am ET
Pieris Pharmaceuticals Presents Preclinical Data for GPC3/4-1BB Bispecific PRS-342 at the 2019 American Association for Cancer Research (AACR) Annual Meeting
BOSTON, MA / ACCESSWIRE / April 2, 2019 / Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for respiratory diseases, cancer and other indications, today announced the presentation of preclinical data for PRS-342, a GPC3/4-1BB immuno-oncology bispecific drug candidate, at a poster session at the 2019 American Association for Cancer Research (AACR) Annual Meeting.
Mar 12, 2019 07:00 am ET
Pieris Pharmaceuticals Reports 2018 Year-End Cash Position and Provides Corporate Update
Company to Host an Investor Conference Call on Tuesday, March 12, 2019 at 8:00 am EDT
Mar 06, 2019 08:00 am ET
Pieris Pharmaceuticals to Present at the Cowen and Company 39th Annual Health Care Conference
BOSTON, MA / ACCESSWIRE / March 6, 2019 / Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for respiratory, cancer and other diseases, announced today that Stephen S. Yoder, President and Chief Executive Officer of Pieris Pharmaceuticals, Inc., will present at the Cowen and Company 39th Annual Health Care Conference in Boston on Wednesday, March 13, 2019 at 10:40 AM (EDT). A webcast of the company's
Mar 05, 2019 08:00 am ET
Pieris Pharmaceuticals to Host Full-Year 2018 Investor Call and Corporate Update on March 12, 2019
BOSTON, MA / ACCESSWIRE / March 5, 2019 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS), a biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for respiratory, cancer and other diseases, announced today that it will host a full-year 2018 investor call on Tuesday, March 12, 2018 at 8:00 AM (EDT) to discuss financial results and provide a corporate update.
Feb 26, 2019 07:45 am ET
Factors of Influence in 2019, Key Indicators and Opportunity within Conagra Brands, Pieris Pharmaceuticals, ArQule, MoneyGram International, Internap, and TIM Participacoes S.A — New Research Emphasiz
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Conagra Brands Inc. (NYSE:CAG), Pieris Pharmaceuticals, Inc....
Nov 27, 2018 08:15 am ET
New Research: Key Drivers of Growth for Martin Midstream Partners, Galectin Therapeutics, Mountain Province Diamonds, MINDBODY, Pareteum, and Pieris Pharmaceuticals — Factors of Influence, Major Initi
In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of Martin Midstream Partners L.P. (NASDAQ:MMLP), Galectin Therapeutics...
Nov 08, 2018 08:00 am ET
Pieris Pharmaceuticals to Present at Investor Conferences in November
Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for cancer, respiratory and other diseases, announced today that members of...
Nov 07, 2018 07:00 am ET
Pieris Pharmaceuticals Reports Third Quarter 2018 Financial Results and Provides Corporate Update
Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for respiratory, cancer and other diseases, today reported financial results...
Oct 31, 2018 08:00 am ET
Pieris Pharmaceuticals to Host Third Quarter 2018 Investor Call and Corporate Update on November 7, 2018
Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS), a biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for cancer, respiratory and other diseases, announced today that it will host a third...
Oct 25, 2018 08:16 am ET
Pieris Pharmaceuticals Appoints Matthew L. Sherman, M.D., to its Board of Directors
Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for cancer, respiratory and other diseases, announced today that Matthew L....
Oct 16, 2018 08:15 am ET
New Research Coverage Highlights Dorian LPG, Avadel Pharmaceuticals, Pieris Pharmaceuticals, Resolute Energy, American Public Education, and THL Credit — Consolidated Revenues, Company Growth, and Exp
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Dorian LPG Ltd. (NYSE:LPG), Avadel Pharmaceuticals PLC. (NASDAQ:AVDL),...
Oct 02, 2018 08:00 am ET
Pieris Pharmaceuticals to Present Preclinical Data for 4-1BB/PD-L1 Bispecific PRS-344/ONC0055 at the Society for Immunotherapy of Cancer (SITC) Annual Meeting
Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for cancer, respiratory and other diseases, announced today that preclinical...
Sep 25, 2018 08:00 am ET
Pieris Pharmaceuticals to Present at Investor Conferences in October
Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for cancer, respiratory and other diseases, announced today that members of...
Sep 14, 2018 08:00 am ET
Pieris Pharmaceuticals to Present Preclinical Data for Inhaled IL-4Rα Antagonist AZD1402/PRS-060 at the ERS International Congress 2018
Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for cancer, respiratory and other diseases, announced today that preclinical...
Sep 10, 2018 08:00 am ET
Pieris Pharmaceuticals Appoints Peter Kiener, D.Phil. to its Board of Directors
Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for cancer, respiratory and other diseases, announced today that Peter...
Sep 04, 2018 08:00 am ET
Pieris Pharmaceuticals Announces Dosing of First Patient in Phase I Combination Trial for PRS-343 Plus Anti-PD-L1 Immunotherapy
Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS), a biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for cancer, respiratory and other diseases, announced today that it has dosed the first...
Aug 30, 2018 08:00 am ET
Pieris Pharmaceuticals to Present at the 20th Annual Rodman & Renshaw Global Investment Conference
Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS), a biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for cancer, respiratory and other diseases, announced today that Stephen Yoder, President and...
Aug 15, 2018 08:00 am ET
New Research Coverage Highlights Cincinnati Bell, BioCryst Pharmaceuticals, Shutterstock, Kopin, Lands' End, and Pieris Pharmaceuticals — Consolidated Revenues, Company Growth, and Expectations for 20
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Cincinnati Bell Inc (NYSE:CBB), BioCryst Pharmaceuticals, Inc....
Aug 09, 2018 07:00 am ET
Pieris Pharmaceuticals Reports Second Quarter 2018 Financial Results and Provides Corporate Update
Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for cancer, respiratory and other diseases, today reported financial results...
Aug 08, 2018 08:00 am ET
Pieris Pharmaceuticals to Present at the 2018 Wedbush PacGrow Healthcare Conference
Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS), a biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for cancer, respiratory and other diseases, announced today that Allan Reine, Senior Vice...
Aug 01, 2018 08:00 am ET
Pieris Pharmaceuticals to Host Second Quarter 2018 Investor Call and Corporate Update on August 9, 2018
Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS), a biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for cancer, respiratory and other diseases, announced today that it will host a second...
May 31, 2018 08:00 am ET
Pieris Pharmaceuticals to Present at Jefferies 2018 Global Healthcare Conference
Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS), a biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for cancer, respiratory and other diseases, announced today that President and CEO Stephen S....
May 10, 2018 07:00 am ET
Pieris Pharmaceuticals Reports First Quarter 2018 Financial Results and Provides Corporate Update
Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for cancer, respiratory and other diseases, today reported financial results...
May 03, 2018 08:00 am ET
Pieris Pharmaceuticals to Present at 43rd Annual Deutsche Bank Health Care Conference
Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS), a biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for cancer, respiratory and other diseases, announced today that Louis Matis, Senior Vice...
Apr 27, 2018 07:35 am ET
Investor Expectations to Drive Momentum within Blackbaud, Pieris Pharmaceuticals, Sarepta Therapeutics, Cambrex, Stoneridge, and First Interstate BancSystem — Discovering Underlying Factors of Influen
NEW YORK, April 27, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Blackbaud, Inc. (NASDAQ:BLKB), Pieris Pharmaceuticals, Inc....
Apr 25, 2018 08:00 am ET
Pieris Pharmaceuticals Appoints Ann Barbier, M.D., Ph.D., to its Board of Directors
Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for cancer, respiratory and other diseases, announced today that Dr. Ann...
Mar 09, 2018 06:00 am ET
Pieris Pharmaceuticals Reports Full-Year 2017 Financial Results and Corporate Update
Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for cancer, respiratory and other diseases, announced today financial results...
Mar 06, 2018 08:30 am ET
Pieris Pharmaceuticals to Present at Investor Conferences in March
Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for cancer, respiratory and other diseases, announced today that Pieris will...
Feb 28, 2018 09:00 am ET
Pieris Pharmaceuticals to Host Full-Year 2017 Investor Call and Corporate Update on March 9, 2018
Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for cancer, respiratory and other diseases, announced today that it will host...
Feb 28, 2018 08:25 am ET
Consolidated Research: 2018 Summary Expectations for Electronics for Imaging, First Hawaiian, Magellan Midstream Partners, Visteon, Pieris Pharmaceuticals, and Cincinnati Bell — Fundamental Analysis,
NEW YORK, Feb. 28, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Electronics for Imaging, Inc. (NASDAQ:EFII), First...
Feb 19, 2018 08:30 am ET
Pieris Pharmaceuticals to Present at the RBC Capital Markets 2018 Global Healthcare Conference
Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for cancer, respiratory and other diseases, announced today that members of...
Feb 16, 2018 05:36 pm ET
Pieris Pharmaceuticals Announces Closing of Public Offering and Exercise of Underwriters' Option to Purchase Additional Shares
Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin technology platform for cancer, respiratory and other diseases, announced today the closing of its...
Feb 14, 2018 12:27 am ET
Pieris Pharmaceuticals Announces Pricing of its Public Offering
Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin technology platform for cancer, respiratory and other diseases, announced today the pricing of its...
Feb 13, 2018 04:01 pm ET
Pieris Pharmaceuticals Announces Public Offering of Common Stock
Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin technology platform for cancer, respiratory and other diseases, announced today that it intends to...
Feb 09, 2018 06:45 am ET
Pieris Pharmaceuticals and Seattle Genetics Announce Multi-Program Immuno-Oncology Collaboration
Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for cancer, respiratory and other diseases, and Seattle Genetics, Inc....
Feb 09, 2018 06:45 am ET
Seattle Genetics and Pieris Pharmaceuticals Announce Multi-Program Immuno-Oncology Collaboration
Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for cancer, respiratory and other diseases, and Seattle Genetics, Inc. (NASDAQ: SGEN), a global biotechnology company developing innovative, targeted therapies for cancer, today announced they have entered into a collaboration and license agreement with the goal of developing multiple targeted bispecific immuno-oncology treatments for solid tumors and blood ca
Jan 29, 2018 08:30 am ET
Pieris Pharmaceuticals to Host Key Opinion Leader Event on February 6th
Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for cancer, respiratory and other diseases, announced today that it will host...
Jan 02, 2018 07:30 am ET
Consolidated Research: 2018 Summary Expectations for Pieris Pharmaceuticals, Cincinnati Bell, FormFactor, Belden, Watts Water Technologies, and Anixter International — Fundamental Analysis, Key Perfor
NEW YORK, Jan. 02, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS), Cincinnati Bell...
Dec 07, 2017 08:30 am ET
Pieris Pharmaceuticals Announces Ethics and Regulatory Clearance to Begin Clinical Testing of Inhaled Respiratory Program, PRS-060/AZD1402
Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for cancer, respiratory and other diseases, announced today that it has...
Nov 21, 2017 08:30 am ET
Pieris Pharmaceuticals Appoints James Geraghty as Chairman of the Board of Directors
Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for cancer, respiratory and other diseases, announced today that James...
Nov 08, 2017 04:30 pm ET
Pieris Pharmaceuticals Reports Financial Results for the Third Quarter Ended September 30, 2017, and Provides Corporate Update
Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for cancer, respiratory and other diseases, today reported financial results...
Nov 02, 2017 08:00 am ET
Pieris Pharmaceuticals to Host Third Quarter 2017 Investor Call and Corporate Update on November 9, 2017
Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for cancer, respiratory and other diseases, announced today that will host a...
Nov 01, 2017 08:00 am ET
Pieris Pharmaceuticals to Present at Investor Conferences in November
Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for cancer, respiratory and other diseases, announced today that members of...
Sep 26, 2017 08:00 am ET
Pieris Pharmaceuticals to Present at the LEERINK Partners Roundtable Series on Thursday, September 28 at 9:30 AM ET
Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for cancer, respiratory and other diseases, announced today that President and...
Aug 10, 2017 08:00 am ET
Pieris Pharmaceuticals Appoints Allan Reine, M.D., as Chief Financial Officer
Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for cancer, respiratory and other diseases, announced that it has appointed...
Aug 09, 2017 05:20 pm ET
Pieris Pharmaceuticals Reports Financial Results for the Second Quarter Ended June 30, 2017 and Provides Corporate Update
Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for cancer, respiratory and other diseases, today reported financial results...
Aug 01, 2017 07:30 am ET
Pieris Pharmaceuticals to Host Second Quarter 2017 Investor Call and Corporate Update on August 10, 2017
Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for cancer, respiratory and other diseases, announced today that it will host...
Jul 05, 2017 04:30 pm ET
Pieris Pharmaceuticals Announces Results from 2017 Annual Meeting of Stockholders and Provides Update on Therapeutic Programs
Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for cancer, respiratory and other diseases, announced today the results from...
Jun 27, 2017 08:00 am ET
Pieris Pharmaceuticals Added to the Russell 2000(R) and Russell 3000(R) Indexes
Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for cancer, respiratory and other diseases, announced today that the Company...
Jun 12, 2017 08:30 am ET
Pieris Pharmaceuticals Announces Expiration of HSR Waiting Period for Collaboration with AstraZeneca
Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for cancer, respiratory and other diseases, announced today that the waiting...
Jun 04, 2017 07:00 am ET
Pieris Pharmaceuticals Announces Presentation of Clinical Data for Anemia Drug Candidate, PRS-080, at the 54th ERA-EDTA Congress
Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for cancer, respiratory and other diseases, announced today the presentation...
Jun 01, 2017 06:19 pm ET
Pieris Pharmaceuticals to Present at The Jefferies 2017 Global Healthcare Conference on Friday, June 9th at 9:00 am EDT
Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for cancer, respiratory and other diseases, announced today that President and...
May 22, 2017 04:32 pm ET
Pieris Pharmaceuticals Appoints James Geraghty to its Board of Directors
Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for cancer, respiratory and other diseases, announced today that James...
May 10, 2017 05:36 pm ET
Pieris Pharmaceuticals Reports Financial Results for the First Quarter Ended March 31, 2017 and Provides Corporate Update
Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for cancer, respiratory and other diseases, today reported financial results...
May 03, 2017 07:30 am ET
Pieris Pharmaceuticals to Host Conference Call on Strategic Alliance With AstraZeneca
Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS), today announced a strategic collaboration in respiratory disease with AstraZeneca to develop novel inhaled biologics that leverage Pieris' Anticalin® platform, led by its drug candidate targeting IL-4...
May 03, 2017 02:00 am ET
Pieris Pharmaceuticals and AstraZeneca Collaborate to Develop and Commercialize Anticalin-Based Inhaled Treatments for Respiratory Diseases
Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS)Pieris to receive $57.5 million USD in upfront and near-term milestone paymentsPieris has the potential to receive development-dependent milestones and eventual commercial payments for all products not...
May 01, 2017 07:30 am ET
Pieris Pharmaceuticals to Host First Quarter 2017 Investor Call and Corporate Update on May 11, 2017
Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS), a biotechnology company advancing its proprietary Anticalin® biotherapeutic technologies, will host a Q1 2017 Investor Call on Thursday, May 11, 2017 at 10:00 AM (EDT) to discuss financial results and...
Apr 04, 2017 07:30 am ET
Pieris Pharmaceuticals Presents IND-enabling Data for Bispecific Immuno-Oncology Drug Candidate, PRS-343, in Poster Session at the 2017 Meeting of the American Association for Cancer Research (AACR)
Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform, announced today the presentation of data informing the design of a...
Mar 22, 2017 08:18 pm ET
Pieris Pharmaceuticals Reports Full-Year 2016 Financial Results and Corporate Update
Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for cancer and other diseases, today reported financial results for the fourth...
Mar 15, 2017 07:30 am ET
Pieris Pharmaceuticals to Host Full-Year 2016 Investor Call And Corporate Update on March 23, 2017
Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS), a biotechnology company advancing its proprietary Anticalin® biotherapeutic technologies, will host a Full-Year 2016 Investor Call on Thursday, March 23, 2017 at 10:00 AM (EDT) to discuss financial...
Mar 14, 2017 07:30 am ET
Pieris Pharmaceuticals to Present at Oppenheimer's 27th Annual Healthcare Conference, Wednesday, March 22nd at 11:30 am EDT
Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS), a biotechnology company advancing its proprietary Anticalin® biotherapeutic technologies, announced today that President and CEO Stephen Yoder will present a corporate overview of the company and meet...
Mar 07, 2017 07:30 am ET
Pieris Pharmaceuticals to Present at the 29th Annual Roth Conference Monday, March 13th at 2:00 pm PST
Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS ), a biotechnology company advancing its proprietary Anticalin® biotherapeutic technologies, announced today that President and CEO Stephen Yoder will present a corporate overview of the Company and meet...
Mar 06, 2017 07:30 am ET
Pieris Pharmaceuticals Announces Presentation of IND-enabling Data for Bispecific Immuno-Oncology Drug Candidate, PRS-343, at the 2017 Meeting of the American Association for Cancer Research (AACR)
Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform, announced today that a set of ex vivo and in vivo data informing the trial...
Mar 01, 2017 08:00 am ET
Pieris Pharmaceuticals to Present at the Cowen and Company 37th Annual Health Care Conference on March 6th at 4:40 pm EST
Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS), a biotechnology company advancing its proprietary Anticalin® biotherapeutic technologies, announced today that President and CEO Stephen Yoder will present a corporate overview of the Company and meet...
Feb 27, 2017 07:30 am ET
Pieris Signs 1st Partnership for Anemia Drug PRS-080, Granting Exclusive Option in Japan to ASKA Pharmaceutical
Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform, today announced that it has granted ASKA Pharmaceutical Co., Ltd., an...
Feb 08, 2017 07:30 am ET
Pieris Pharmaceuticals to Present at the Bio CEO Investor Conference on February 13th at 1:30 pm EST
Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS), a biotechnology company advancing its proprietary Anticalin® biotherapeutic technologies, announced today that President and CEO Stephen Yoder will present a corporate overview of the Company and meet...
Feb 07, 2017 05:21 pm ET
Pieris Announces Management Transition
Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform, today announced that Darlene Deptula-Hicks has submitted her resignation,...
Jan 05, 2017 07:30 am ET
Pieris Pharmaceuticals to Host Investor Call Today to Discuss Servier Collaboration
Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for cancer and other diseases, announced it will host an investor conference...
Jan 05, 2017 07:00 am ET
Pieris Pharmaceuticals and Servier Forge Strategic Immuno-oncology Co-development Alliance
Pieris and Servier, an independent international pharmaceutical company headquartered in France with annual sales of more than EUR4 billion, to jointly pursue several bispecific therapeutic programs including Pieris' proprietary dual checkpoint...
Dec 01, 2016 08:00 am ET
Pieris Pharmaceuticals Appoints Claude Knopf as Chief Business Officer
Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for cancer and other diseases, today announced that it has appointed Claude...
Nov 09, 2016 05:50 pm ET
Pieris Pharmaceuticals Reports Financial Results and Provides Corporate Update for the Third Quarter Ended September 30, 2016
Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for cancer and other diseases, today reported financial results for the third...
Nov 01, 2016 08:00 am ET
Pieris Pharmaceuticals to Host Third Quarter 2016 Investor Call and Corporate Update on November 10, 2016
Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS), a clinical stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for cancer and other diseases, will host a third quarter 2016 investor...
Oct 26, 2016 08:00 am ET
Pieris Pharmaceuticals to Receive GLP Tox Milestone Payment in Daiichi Sankyo Collaboration
Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for cancer and other diseases, announced today the achievement of a...
Oct 20, 2016 08:00 am ET
Pieris Announces Presentations at Upcoming R&D Conferences
Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for cancer and other diseases, announced today presentations at two upcoming...
Sep 26, 2016 05:15 pm ET
Pieris Pharmaceuticals Presents Positive Data for Its Lead Bispecific Drug Candidate, PRS-343, at the 2016 CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference
Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS), a biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform, announced that it has today presented new preclinical data demonstrating in vivo efficacy of...
Sep 22, 2016 08:00 am ET
Pieris Pharmaceuticals Appoints Christopher Kiritsy to Its Board of Directors
Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for cancer and other diseases, announced today that Christopher Kiritsy has...
Sep 07, 2016 08:30 am ET
Pieris Pharmaceuticals Announces Presentation of Data for Its Lead IO Bispecific Program, PRS-343, at the 2016 CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference
Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for cancer and other diseases, announced today that it will be presenting a...
Sep 01, 2016 10:31 am ET
Pieris Pharmaceuticals to Present at Rodman & Renshaw 18th Annual Global Investor Conference
Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for cancer and other diseases, announced today that its President and CEO,...
Aug 10, 2016 05:00 pm ET
Pieris Pharmaceuticals Reports Financial Results and Provides Corporate Update for the Second Quarter Ended June 30, 2016
Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for cancer and other diseases, today reported financial results for the second...
Aug 01, 2016 08:00 am ET
Pieris Pharmaceuticals to Host Second Quarter 2016 Investor Call and Corporate Update on August 11, 2016
Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS), a clinical stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for cancer and other diseases, will host a second quarter 2016 investor...
Jul 26, 2016 08:00 am ET
Pieris Pharmaceuticals Appoints Julian Adams, Ph.D., to Its Board of Directors
Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for cancer and other diseases, announced today that Julian Adams, Ph.D., has...
Jun 14, 2016 07:59 am ET
Pieris Pharmaceuticals Announces Participation at Two Upcoming Investor Conferences
Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for cancer and other diseases, announced today its participation at the Roth...
Jun 08, 2016 11:20 am ET
Pieris Pharmaceuticals Announces Closing of $16.5 Million Private Placement
Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS) today announced closing of the private placement consisting of 8,188,804 units at a price of $2.015 per unit, for total gross proceeds of approximately $16.5 million, before deducting placement agent fees...
Jun 03, 2016 09:00 am ET
Pieris Pharmaceuticals Announces $16.5 Million Private Placement
Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS) announced today that it entered into a securities purchase agreement for a private placement with a select group of institutional investors, including lead investor BVF Partners L.P. and its...
May 11, 2016 05:00 pm ET
Pieris Pharmaceuticals Reports Financial Results and Corporate Update for the First Quarter Ended March 31, 2016
Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for cancer and other diseases, today reported financial results for the first...
Apr 27, 2016 08:00 am ET
Pieris Pharmaceuticals to Host First Quarter 2016 Investor Call and Corporate Update on May 12, 2016
Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS), a biotechnology company advancing its proprietary Anticalin® biotherapeutic technologies, will host a first quarter 2016 investor conference call on Thursday, May 12, 2016 at 10:00 am Eastern time to...
Mar 22, 2016 04:05 pm ET
Pieris Pharmaceuticals Reports Full-Year 2015 Financial Results and Corporate Update
Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS), a biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform, announced today 2015 corporate highlights, a clinical development overview and financial...
Mar 17, 2016 08:00 am ET
Pieris Pharmaceuticals Announces Presentation of In Vivo Preclinical Data for Its Lead Bispecific Immuno-Oncology Drug Candidate, PRS-343, at the 2016 Annual Meeting of the American Association for Ca
Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS), a biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform, announced today that in vivo proof of concept data for anti-tumor activity of PRS-343, the...
Mar 03, 2016 08:00 am ET
Pieris Pharmaceuticals to Host Full-Year 2015 Investor Call and Corporate Update on March 23, 2016
Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS), a biotechnology company advancing its proprietary Anticalin® biotherapeutic technologies, will host a year-end 2015 investor conference call on Wednesday, March 23, 2016 at 10:00 am Eastern time to...
Mar 02, 2016 08:00 am ET
Pieris Pharmaceuticals to Present at the Cowen & Company 36th Annual Healthcare Conference on March 9th at 10:00 am ET
Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS), a biotechnology company advancing its proprietary Anticalin® bio therapeutic technologies, announced today that CEO Stephen Yoder will present a corporate overview of the Company and participate in a...
Feb 29, 2016 08:55 am ET
Pieris Pharmaceuticals to Present at the 28th Annual ROTH Conference on March 15th at 10:30 am PDT
Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS), a biotechnology company advancing its proprietary Anticalin® bio therapeutic technologies, announced today that CEO Stephen Yoder will present a corporate overview of the Company and meet with investors...
Jan 28, 2016 08:30 am ET
Pieris Pharmaceuticals to Present at the 18th Annual BIO CEO and Investor Conference on February 8th at 9:30 am ET
Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS), a biotechnology company advancing its proprietary Anticalin® bio therapeutic technologies, announced today that its President and CEO, Stephen Yoder, will present at the 18th Annual BIO CEO and Investor...

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please log in or subscribe.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.